Cybin Inc. has received a US patent for its CYB005 phenethylamines program, which focuses on developing non-hallucinogenic molecules for Central Nervous System (CNS) disorders. This patent further strengthens Cybin’s commitment to research beyond its clinical tryptamine programs and highlights the potential of non-hallucinogenic 5-HT receptor agonists for treating CNS disorders. The company continues to progress with its clinical-stage psychiatry programs, CYB003 and CYB004, for major depressive disorder and Generalized Anxiety Disorder, respectively.